BR112016022011A2 - ?antígeno de proteína estafilocócica a mutante, proteína de fusão, e, composição imunogênica? - Google Patents

?antígeno de proteína estafilocócica a mutante, proteína de fusão, e, composição imunogênica?

Info

Publication number
BR112016022011A2
BR112016022011A2 BR112016022011A BR112016022011A BR112016022011A2 BR 112016022011 A2 BR112016022011 A2 BR 112016022011A2 BR 112016022011 A BR112016022011 A BR 112016022011A BR 112016022011 A BR112016022011 A BR 112016022011A BR 112016022011 A2 BR112016022011 A2 BR 112016022011A2
Authority
BR
Brazil
Prior art keywords
immunogenic composition
fusion protein
protein
mutant staphylococcal
antigen
Prior art date
Application number
BR112016022011A
Other languages
English (en)
Other versions
BR112016022011B1 (pt
Inventor
Bagnoli Fabio
Fiaschi Luigi
Scarselli Maria
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of BR112016022011A2 publication Critical patent/BR112016022011A2/pt
Publication of BR112016022011B1 publication Critical patent/BR112016022011B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

é provido spa mutante com afinidade diminuída para a porção fc¿ de igg humana. a imunização com esxa, esxb, fhud2, sta011, hla e o dito spa mutante provê resultados surpreendentes em um modelo de abscesso renal de infecção pela s. aureus.
BR112016022011-0A 2014-03-26 2015-03-24 Antígeno de proteína estafilocócica a mutante, proteína de fusão, e,composição imunogênica BR112016022011B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14161861 2014-03-26
EP14161861.1 2014-03-26
EP14192913.3 2014-11-12
EP14192913 2014-11-12
PCT/EP2015/056175 WO2015144653A1 (en) 2014-03-26 2015-03-24 Mutant staphylococcal antigens

Publications (2)

Publication Number Publication Date
BR112016022011A2 true BR112016022011A2 (pt) 2017-10-24
BR112016022011B1 BR112016022011B1 (pt) 2024-04-16

Family

ID=

Also Published As

Publication number Publication date
JP2017511312A (ja) 2017-04-20
BE1022857A1 (fr) 2016-09-27
LT3122378T (lt) 2020-02-10
HUE047808T2 (hu) 2020-05-28
JP6894237B2 (ja) 2021-06-30
PL3122378T3 (pl) 2020-06-01
ZA201605818B (en) 2022-05-25
EP3122378A1 (en) 2017-02-01
SG11201606887WA (en) 2016-09-29
KR20190110655A (ko) 2019-09-30
BE1022744B1 (fr) 2016-08-29
CA2942450A1 (en) 2015-10-01
CN106103469A (zh) 2016-11-09
PT3122378T (pt) 2020-03-04
IL247328B (en) 2021-04-29
RS59971B1 (sr) 2020-03-31
WO2015144653A1 (en) 2015-10-01
HRP20200217T1 (hr) 2020-05-15
JP2021035950A (ja) 2021-03-04
KR20160132109A (ko) 2016-11-16
IL282104A (en) 2021-05-31
US10328140B2 (en) 2019-06-25
IL247328A0 (en) 2016-09-29
DK3122378T3 (da) 2020-03-02
EP3639850A1 (en) 2020-04-22
AU2015238512A1 (en) 2016-10-13
MX2016012538A (es) 2016-12-14
AU2015238512B2 (en) 2018-02-01
EA037818B1 (ru) 2021-05-25
CN106103469B (zh) 2020-11-27
CY1122537T1 (el) 2021-01-27
BE1022744A1 (fr) 2016-08-29
KR102297357B1 (ko) 2021-09-02
KR102027429B1 (ko) 2019-10-01
KR20190040101A (ko) 2019-04-16
SI3122378T1 (sl) 2020-03-31
US20180064800A9 (en) 2018-03-08
CN112521464A (zh) 2021-03-19
EA201691502A1 (ru) 2017-04-28
US20170143816A1 (en) 2017-05-25
WO2015144655A1 (en) 2015-10-01
ES2769647T3 (es) 2020-06-26
EP3122378B1 (en) 2019-12-11

Similar Documents

Publication Publication Date Title
SV2018005659A (es) Anticuerpos agonistas que se unen especificamente a cd40 humanos y metodos de uso
CY1122537T1 (el) Μεταλλακτικα σταφυλοκοκκικα αντιγονα
EP3362479A4 (en) FOR HUMANESE CD19 SPECIFIC ANTIBODY AGENTS AND USES THEREOF
TWD188267S (zh) 醫療錄影機
BR112016015140A2 (pt) imunoglobulina com fabs in-tandem e usos das mesmas
SG10201806108TA (en) Binding proteins and methods of use thereof
BR112018074056A2 (pt) composições e métodos relacionados a construtos de fc manipulados
EP4272750A3 (en) Protein antigens that provide protection against pneumococcal colonization and/or disease
BR112019005139A2 (pt) anticorpos anti-il-33 e usos dos mesmos
EA201600473A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Tau(PS422) И СПОСОБЫ ПРИМЕНЕНИЯ
DE112019001759A5 (de) Kupplungsscheibe mit reibeinrichtung aufweisendem pendelwippendämpfer; sowie reibkupplung
BR112014032636A2 (pt) Vacinas atenuadas de streptococcus suis e métodos de produção e usos das mesmas
BR112016012024A2 (pt) vacina contra colibacilose
MY191539A (en) Streptococcal vaccine
NZ710744A (en) Methods for increasing immunoglobulin a levels
MY191217A (en) Group a streptococcus vaccine
BR112017009560A2 (pt) preparação de material microporoso compósito baseado quitosana e suas aplicações
EP3491386A4 (en) IMMUNOASSAY METHODS AND COMPOSITIONS FOR DETECTING INFECTIONS USING TESTANTIGENS AS CROSS-REACTIVE CONTROLLING ANTIQUE
BR112017002173A2 (pt) anticorpos semelhantes à angiopoietina e métodos de uso
UY36261A (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
EP4011919A3 (en) Relaxin immunoglobulin fusion proteins and methods of use
ES2721935T3 (es) Anticuerpos anti-BAG3 para uso terapéutico
BR112014020025A8 (pt) Vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas
MX2019008779A (es) Antigenos de pseudomonas y combinaciones de antigenos.
EP3078677A4 (en) Antigen chimera, antigen combination, vaccine, method of preparing same, and kit thereof

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/03/2015, OBSERVADAS AS CONDICOES LEGAIS